- Venetoclax Regimens in Acute Myeloid Leukemia: Do We Have the Answers?January 13, 2020 | Kristen M. O'Dwyer, MD | Eric Huselton, MD
Dr. O'Dwyer and Dr. Huselton look at studies that observe the use of venetoclax regimens to treat acute myeloid leukemia in older patients or patients with comorbidities unable to use intensive induction chemotherapy.
- How To Treat the Patient With Antiphospholipid Antibody Syndrome Who Needs Anticoagulation?January 09, 2020 | Stephan Moll, MD
Dr. Moll discusses three significant publications from 2019 on antiphospholipid syndrome.
- Resolving to Close the GapJanuary 09, 2020 | Laura C. Michaelis, MD
Dr. Laura Michaelis ushers in 2020 introducing the 2019 "Year's Best" articles from our Contributing Editors while stressing challenges that remain in the translation of science into the public good and proposing some resolutions to help drive progress.
- Germline Predisposition to Childhood Leukemia: T-ALL Risk Variants Uncovered in GWASJanuary 08, 2020 | Suzanne P. MacFarland, MD | David T. Teachey, MD
Drs. MacFarland and Teachey discuss genome-wide association studies that shed light on germline predisposition to childhood leukemia.
- The Year's Best in Sickle Cell Disease: A Global Perspective on Pregnancy in 2019January 07, 2020 | Ahmar U. Zaidi, MD | Ifeyinwa (Ify) Osunkwo, MD, MPH
Dr. Zaidi and Dr. Osunkwo discuss efforts in 2019 to patch the gaps in our knowledge and understanding relating to both maternal and fetal management and outcomes of pregnancy in sickle cell disease.
- Mapping Functional Susceptibilities in AMLJanuary 06, 2020 | Andrea Henden, MBBS, PhD, FRACP, FRCPA | Steven Lane, MBBS, PhD, FRACP, FRCPA
Dr. Henden and Dr. Lane discuss work that sheds light on how mutations in acute myeloid leukemia contribute to leukemogenesis, providing rationale for precision-based therapies aimed at specific disease biology.
- Antibody-drug Conjugates Change the Standard of Care for Both B- and T-cell Non-Hodgkin LymphomaJanuary 02, 2020 | Caron A. Jacobson, MD
Dr. Jacobson covers studies that evaluate antibody-drug conjugates to change the standard of care for B- and T-cell non-Hodgkin lymphoma.
- Direct Oral Anticoagulant Thromboprophylaxis Trials for Ambulatory Cancer Patients: Guideline Changing, but Are They Practice Changing?January 02, 2020 | Lori-Ann Linkins, MD, MSc(Clin Epi), FRCPC
Dr. Linkins discusses direct oral anticoagulant thromboprophylaxis trials that compare risks and benefits for patients who are hospitalized or undergoing surgery.
- The Moving Target of When to Treat on the Myeloma SpectrumJanuary 02, 2020 | Oliver C. Lomas, MD, PhD | Irene M. Ghobrial, MD
Drs. Lomas and Ghobrial discuss trials from 2019 that assessed intervention in smoldering multiple myeloma (SMM) to determine whether the standard of practice to treat patients with high-risk SMM should change.
- 2019 Brings Biologic Understanding and Hope for Patients With TP53 Mutated Myelodysplastic SyndromeDecember 26, 2019 | Theodoros Karantanos, MD, PhD | Amy DeZern, MD, MHS
Drs. DeZern and Karantanos share exciting findings in the biologic understanding of TP53-mutated myelodysplastic syndromes which allow for future refinement to current therapeutic algorithms.
- Are You a Lumper or a Splitter? Embrace the Genomic Spectrum of Neutrophilic Myeloid NeoplasmsDecember 26, 2019 | Christopher B. Hergott, MD, PhD | Annette S. Kim, MD, PhD
Drs. Hergott and Kim provide an overview of work done in 2019 to expand our molecular understanding of chronic myeloid neoplasms that challenges long-held views on how to classify and diagnose them.
- Frontline CLL Options: An Embarrassment of Riches?December 26, 2019 | Brad Kahl, MD
Dr. Kahl discusses four important studies published in 2019 that have evaluated novel targeted agents for not-yet treated chronic lymphocytic leukemia.